CF
NRIX icon

Corebridge Financial’s Nurix Therapeutics NRIX Stock Holding History

Corebridge Financial’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,849
Closed -$438K – 1829
2025
Q1 		$438K Buy
36,849
+1,942
+6% +$32.5K ﹤0.01% 1670
2024
Q4 		$658K Buy
34,907
+770
+2% +$17.6K ﹤0.01% 1534
2024
Q3 		$767K Buy
34,137
+1,580
+5% +$35.8K ﹤0.01% 1499
2024
Q2 		$679K Buy
+32,557
New +$507K ﹤0.01% 1539

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Corebridge Financial's NRIX Position: Q2 2025 in Review

Corebridge Financial sold out of Nurix Therapeutics (NRIX) in Q2 2025, closing a stake of 36,849 shares — an estimated $438K sold.

Corebridge Financial first reported a position in NRIX in Q2 2024 and held it in 4 quarters. The position peaked at $767K in Q3 2024. 163 funds tracked by Wall St. Rank hold NRIX as of Q2 2025.

  • Corebridge Financial reported no remaining Nurix Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 36,849 Nurix Therapeutics shares in Q2 2025, an estimated $438K.
  • Corebridge Financial first reported a position in Nurix Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Nurix Therapeutics position peaked at $767K in Q3 2024.
  • 163 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.